• Keros Therapeutics director Julius Knowles sold 2,625 common shares on June 4, 2026 at USD 10.73.
• Directly held stake fell to 10,958 shares following the sale.
• He also reported indirect holdings of 150,047 shares and 102,233 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001808365-26-000004), on June 08, 2026, and is solely responsible for the information contained therein.